Promoting effects of IL-13 on Ca2+ release and store-operated Ca2+ entry in airway smooth muscle cells

Pulm Pharmacol Ther. 2010 Jun;23(3):182-9. doi: 10.1016/j.pupt.2009.12.005. Epub 2010 Jan 4.

Abstract

Th2 cytokine interleukin (IL)-13 plays a central role in the pathogenesis of allergic asthma. IL-13 exhibits a direct effect on airway smooth muscle cells (ASMCs) to cause airway hyperresponsiveness. IL-13 has been demonstrated to regulate Ca(2+) signaling in ASMCs, but the underlying mechanisms are not fully understood. Store-operated Ca(2+) entry (SOCE) plays an important role in regulating Ca(2+) signaling and cellular responses of ASMCs, whether IL-13 affects SOCE in ASMCs has not been reported. In this study, by using confocal Ca(2+) fluorescence imaging, we found that IL-13 (10 ng/ml) treatment increased basal intracellular Ca(2+) ([Ca(2+)](i)) level, Ca(2+) release and SOCE induced by SERCA inhibitor thapsigargin in rat bronchial smooth muscle cells. The glucocorticoid dexamethasone and the short-acting beta2 adrenergic agonist (beta2 agonist) salbutamol suppressed IL-13-augumented basal [Ca(2+)](i), Ca(2+) release and SOCE, whereas the long-acting beta2 agonist salmeterol had no effect on altered Ca(2+) signaling in IL-13-treated ASMCs. Membrane-permeable cAMP analog dibutyryl-cAMP (db-cAMP) similarly decreased Ca(2+) release and SOCE induced by thapsigargin in IL-13-treated ASMCs, confirmed a role of cAMP/PKA signaling pathway in the regulation of SOCE. IL-13 promoted the proliferation of ASMCs stimulated by serum; this effect was inhibited by nonspecific Ca(2+) channel blockers SKF-96365 and NiCl(2), by salmeterol, but not by salbutamol and dexamethasone. IL-13 treatment did not change the expression of SOC channel-associated molecules STIM1, Orai1 and TRPC1 at mRNA level. Our findings identified a promoting effect of IL-13 on Ca(2+) release and SOCE in ASMCs, which partially contributes to its effect on the proliferation of ASMCs; the differences of glucocorticoids and beta2 agonists in inhibiting Ca(2+) signal and proliferation potentiated by IL-13 suggest that these therapies of asthma may have distinct effect on the relief of airway contraction and remodeling in bronchial asthma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albuterol / pharmacology
  • Animals
  • Bronchi / cytology
  • Bronchi / drug effects*
  • Bronchi / metabolism
  • Bronchodilator Agents / pharmacology
  • Bucladesine / pharmacology
  • Calcium / metabolism*
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels / physiology
  • Calcium Signaling / drug effects
  • Dexamethasone / pharmacology
  • In Vitro Techniques
  • Interleukin-13 / pharmacology*
  • Interleukin-13 / physiology
  • Male
  • Myocytes, Smooth Muscle / drug effects*
  • Myocytes, Smooth Muscle / metabolism
  • Rats
  • Thapsigargin / pharmacology

Substances

  • Bronchodilator Agents
  • Calcium Channel Blockers
  • Calcium Channels
  • Interleukin-13
  • Bucladesine
  • Thapsigargin
  • Dexamethasone
  • Albuterol
  • Calcium